comprehensive -WSS

comprehensive

author：entertainment 2025-08-28 04:23:22 - browse：94

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Gene editing the human germline: What are the risks?

leisure time

WSS

SCOTUS questions limit to govt efforts to fight misinformation

Inequities make cancer less preventable for women: report

Virtual Event: March of the Biosimilars

5 to watch: Tech startups trying to solve health care's staffing crisis

SCOTUS questions limit to govt efforts to fight misinformation

Stop the failed accountable care organization experiment

knowledge

comprehensive

focus

Apple is now the first public company to be valued at $3 trillion

UnitedHealth increases loan offers after Change Healthcare outage

Sports medicine is finally prioritizing gender equality

Argenx readies a blockbuster opportunity with drug for autoimmune disease

The high cost of giving birth even with insurance

Neuroscience’s long legacy of racism

Duchenne breakthrough therapy leaves behind pioneering families

FDA advisers vote against ALS treatment from BrainStorm

DIEP, the 'gold standard' of breast reconstruction, is under threat

Health tech startups drop sharply from 2021 highs

focus

Neuroscience’s long legacy of racism

Mindstrong's demise and the future of mental health care

Medicaid, Medicare dual

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Future doctors should be trained to promote social change

Paxlovid should be available without a positive Covid test

Wikipedia

knowledge

leisure time

focus